Document Detail


Ursodeoxycholic acid therapy in hepatobiliary disease.
MedLine Citation:
PMID:  10781781     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ursodeoxycholic acid is a hydrophilic bile acid that under normal circumstances represents a small fraction of the bile acid pool in humans. It is effective in dissolving cholesterol gallstones in appropriately selected patients. Ursodeoxycholic acid improves serum alkaline phosphatase and aminotransferase levels in primary biliary cirrhosis, but its effects on rates of liver transplantation and death are less certain. Ursodeoxycholic acid has had promising [corrected] effects in several other cholestatic liver diseases, such as cystic fibrosis and intrahepatic cholestasis of pregnancy, but data are too preliminary to make recommendations about its routine use in these conditions. Its effects are mediated by amelioration of damage to cell membranes caused by retained toxic bile acids. Ursodeoxycholic acid improves biliary secretion of bile acids, may improve bile flow, and it has immunomodulatory properties that may reduce immune-mediated liver damage. However, its use in the treatment of cholestatic liver disease remains uncertain pending additional randomized trials.
Authors:
K V Kowdley
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  108     ISSN:  0002-9343     ISO Abbreviation:  Am. J. Med.     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-06-16     Completed Date:  2000-06-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  481-6     Citation Subset:  AIM; IM    
Affiliation:
Division of Gastroenterology/Hepatology, University of Washington, School of Medicine, Seattle, Washington, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biliary Tract Diseases / drug therapy*,  etiology
Bone Marrow Transplantation / adverse effects
Cholagogues and Choleretics / immunology,  pharmacology,  therapeutic use*
Cholangitis, Sclerosing / complications
Cholestasis / drug therapy*,  etiology
Chronic Disease
Cystic Fibrosis / complications
Female
Graft Rejection / complications
Graft vs Host Disease / complications
Humans
Liver Cirrhosis, Biliary / complications
Liver Diseases / drug therapy*,  etiology
Liver Transplantation / adverse effects
Parenteral Nutrition, Total / adverse effects
Pregnancy
Pregnancy Complications
Ursodeoxycholic Acid / immunology,  pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Cholagogues and Choleretics; 128-13-2/Ursodeoxycholic Acid
Comments/Corrections
Erratum In:
Am J Med 2000 Jun 1;108(8):690

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patient centeredness in medical encounters requiring an interpreter.
Next Document:  Thalidomide: current and potential clinical applications.